Market Risers: Anglo American, Ashtead Group, AstraZeneca, Biome Technologies

Broker Ratings

Shares of Anglo American company symbol: LON:AAL has gained 2.29% or 57.5 points throughout the session so far. Buyers seem confident while the stock has been in play. The high for the period has reached 2591 while the low for the session was 2534. The amount of shares exchanged has so far reached 1,393,881 while the daily average number of shares exchanged is 4,594,965. A 52 week share price high is 3509 which is 993 points difference from the previous days close and putting the 52 week low at 1755.2 which is a variance of 760.8 points. Anglo American now has a 20 SMA at 2897.63 and now a 50 day moving average now of 3078.18. This puts the market capitalisation now at £34,843.31m at the time of this report. The share price is in GBX. Mcap is measured in GBP. This article was written with the last trade for Anglo American being recorded at Wednesday, September 29, 2021 at 1:05:33 PM GMT with the stock price trading at 2573.5 GBX.

Shares of Ashtead Group ticker code: LON:AHT has stepped up 2.64% or 148 points during today’s session so far. Buyers have stayed positive throughout the trading session. The period high has peaked at 5782 while the low for the session was 5614.22. The total volume of shares exchanged through this period comes to 156,493 with the average number of shares traded daily being 850,330. The 52 week high for the shares is 6284 which is 676 points difference from the previous close and the 52 week low at 2742 a difference of some 2866 points. Ashtead Group now has a 20 SMA at 5915.87 with a 50 day MA at 5726.07. The market capitalisation is now £25,717.37m at the time of this report. All share prices mentioned for this stock are traded in GBX. Mcap is measured in GBP. This article was written with the last trade for Ashtead Group being recorded at Wednesday, September 29, 2021 at 1:06:06 PM GMT with the stock price trading at 5756 GBX.

Shares of AstraZeneca ticker code: LON:AZN has risen 3.52% or 298 points during today’s session so far. Buyers are a positive bunch while the stock has been in play. The periods high has already touched 8778 and hitting a low of 8559. The number of shares traded by this point in time totalled 826,890 with the daily average number around 2,305,384. The 52 week high is 8982 around 508 points difference from the previous days close and the 52 week low at 6736 a difference of some 1738 points. AstraZeneca has a 20 SMA of 8529.61 and also a 50 day simple moving average now at 8500.02. This puts the market cap at £135,774.81m at the time of this report. The stock is traded in GBX. Mcap is measured in GBP. This article was written with the last trade for AstraZeneca being recorded at Wednesday, September 29, 2021 at 1:06:04 PM GMT with the stock price trading at 8772 GBX.

Stock in Biome Technologies company symbol: LON:BIOM has climbed 4.52% or 19 points during today’s session so far. Traders have so far held a positive outlook throughout the session. The high for the period has reached 439 and a low of 425.5. The number of shares traded by this point in time totalled 3,233 with the average number of shares traded daily being 3,032. A 52 week high for the stock is 510 which is 90 points difference from the previous days close and putting the 52 week low at 120 is a variance of 300 points. Biome Technologies now has a 20 SMA of 414.97 and a 50 day moving average of 412.21. The market capitalisation is now £16.49m at the time of this report. The share price is in Great British pence. Mcap is measured in GBP. This article was written with the last trade for Biome Technologies being recorded at Wednesday, September 29, 2021 at 11:16:26 AM GMT with the stock price trading at 439 GBX.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

AstraZeneca wins US approval for Imfinzi in early gastric and GEJ cancers

AstraZeneca has received US approval for Imfinzi combined with FLOT chemotherapy for adults with resectable early-stage and locally advanced gastric and gastroesophageal junction cancers.

AstraZeneca Plc to invest $2 billion in major Maryland manufacturing expansion

AstraZeneca has confirmed a $2 billion investment to expand its manufacturing presence in Maryland, including a larger biologics facility in Frederick and a new clinical manufacturing site in Gaithersburg.

Anglo American delivers solid Q3 2025 performance with higher guidance at Minas-Rio

Anglo American has reported a strong third quarter for 2025, with solid performances in copper and iron ore driving results. Copper output rose 1% year-on-year to 184,000 tonnes, supported by higher grades at Quellaveco and Los Bronces, while Minas-Rio’s iron ore guidance was raised to 23–25 Mt following a successful pipeline inspection.

AstraZeneca Tezspire approved in the US for chronic rhinosinusitis with nasal polyps

The US FDA has approved AstraZeneca and Amgen’s Tezspire (tezepelumab) as an add-on maintenance treatment for patients aged 12 and over with inadequately controlled chronic rhinosinusitis with nasal polyps.

AstraZeneca Plc reaches agreement with Trump administration to cut US drug prices

AstraZeneca has signed a landmark agreement with President Donald J. Trump’s administration to reduce the cost of prescription medicines for American patients.

Anglo American Plc confirms merger rationale following Teck operational review

Anglo American plc has stated that Teck Resources’ updated operational outlook is consistent with its due diligence, confirming the strategic rationale and expected synergies of their planned merger.

Search

Search